Sangamo Biosciences (SGMO)
- On 1:00 am EDT, Thursday October 15, 2009
Sangamo Biosciences, Inc. (NasdaqGM: SGMO - News) uses a proprietary ZFP gene regulation technology to discover and develop a new class of therapeutic candidates for diabetic neuropathy, cardiovascular disease, cancer and immune diseases.
We are optimistic about this novel technology. SB-509 has shown some positive results for the treatment of moderate to severe DN. We are also optimistic about other clinical programs. Further, we are impressed by the company's strategy to monetize this ZFP technology.
We maintain our Outperform rating on shares of Sangamo based on the platform technology and the progress the company has made for both its clinical and preclinical programs. Our target price is $10.00.
SANGAMO BIOSCI (SGMO): Free Stock Analysis Report
|
Related Headlines
- Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS - PR Newswire
- SANGAMO BIOSCIENCES INC Files SEC form 10-Q, Quarterly Report - EDGAR Online
- Sangamo 3Q loss narrows on payments, lower costs - AP
- New Star Analyst Rankings for Sangamo BioSciences, Inc. - StarMine
- Sangamo Biosciences, Inc. Q3 2009 Earnings Call Transcript - at Seeking Alpha
Related Blog Headlines
Sponsored Links
-
Yahoo Personal Free Trial
Sign Up for a 7 Day Free Trial. Start Emailing, Flirting & Dating. -
Buy Stocks - $4 Fee at ShareBuilder
No account or investment minimums. No inactivity fees. Start today.
-
Independent Advisor Broker/Dealer
Discover The Many Benefits Of Independence With LPL Financial. -
Personal Finance Budgeting
What you need to know. Personal finance management tips and advice.
More From Provider
Tech Ticker Recent Posts
- Are We Really Better Off Than We Were a Year Ago? - Peter Gorenstein
- Dollar Slumps After Fed Talks Turkey: Can Stocks Keep Up with Gold? - Aaron Task
- Don't Blame the Shorts: A History of Misplaced Aggression - Heesun Wee
Add Alert © 2009 Zacks.com. All rights reserved.